Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
基本信息
- 批准号:9767131
- 负责人:
- 金额:$ 35.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-06 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAffinityAgonistAnimal ModelAnimalsAnteriorBehaviorBehavioralBehavioral MechanismsBody WeightBody Weight ChangesBody Weight decreasedBody fatBrainBrain regionCardiovascular DiseasesCholinergic ReceptorsCognitionCoronary heart diseaseCuesDesire for foodDiabetes MellitusDiseaseDopamineEatingEnergy IntakeEnergy MetabolismFatty acid glycerol estersFeeding PatternsFoodFood Intake RegulationFunctional disorderGeneral PopulationGoalsHealthHumanHungerHypertensionHypothalamic structureIndividualInsula of ReilKnowledgeMalignant NeoplasmsMeasuresMetabolicMusculoskeletal DiseasesNeuroanatomyNeurobiologyNeuronsNicotineNicotinic AgonistsNicotinic ReceptorsObesityOutcomeOverweightPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlacebosPlayProcessPublic HealthQuality of lifeResearchResearch DesignRestRewardsRisk FactorsRoleSatiationSchizophreniaStrategic PlanningStudy modelsThinnessUnited States National Institutes of HealthVentral StriatumVisualWeightWeight GainWeight maintenance regimenadult obesityanabaseinebehavior measurementcholinergicfeedingimprovedmortality riskmouse modelnerve supplynovelnovel strategiespublic health relevancereceptor expressionresponsetreatment strategyweight maintenance
项目摘要
DESCRIPTION (provided by applicant): Obesity is a profound public health issue, associated with increased mortality and risk for multiple diseases, including cardiovascular disease, diabetes, musculoskeletal disorders, and cancer. Weight loss in obese individuals reduces many of these risk factors, but weight loss and maintenance can be extremely difficult. Clearly, developing new approaches to treat obesity is an important goal, and is a key component of the Strategic Plan for NIH Obesity Research. A possible novel mechanism for treating obesity is activation of the a7 nicotinic cholinergic receptor. Nicotine's association with reduced body weight, and its ability to suppress appetite, increase energy expenditure and alter feeding patterns is well established. Recent evidence suggests that the a7 nicotinic receptor may play a particularly prominent role in these effects. Recent findings by our group separately examining the neuronal mechanisms of food intake behavior in non-mentally ill subjects and the neurobiology of nicotinic cholinergic dysfunction in schizophrenia unexpectedly have converged, showing that some of the same brain intrinsic network components that are overactive in obese individuals are down-modulated by an a7 nicotinic receptor agonist in patients. Given these effects, we recently conducted an initial study of the effect of the a7 nicotinic receptor partial agonist 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A) on weight, appetite and neuronal measures of the response to visual food cues in patients. These measures were an add- on outcome of a study designed to examine drug effects on cognition. Compared to placebo, DMXB-A was associated with significant weight loss and a reduction in hunger and appetite. Neuronally, DMXB-A was associated with alterations in the same brain regions we previously found to be involved in the response to food intake in lean compared to obese-prone individuals. We also found that the DMXB-A-associated change in insula response to food cues was related to weight change. Considering these preliminary results, and emerging evidence from animal studies, activation of a7 nicotinic receptors may be a novel mechanism to alter neuronal processes of food intake behavior and improve weight management in overweight/obese individuals in the general population. The overall goal of this application is to understand the effects of an a7 nicotinic receptor partial agonist on neuronal, physiological, and behavioral mechanisms of obesity in the general population. It is hoped that results of this study will inform
our knowledge of nicotinic cholinergic involvement in obesity, potentially leading to novel treatment strategies to address a critical problem that negatively impacts health and quality of life.
描述(由申请人提供):肥胖是一个严重的公共卫生问题,与多种疾病(包括心血管疾病、糖尿病、肌肉骨骼疾病和癌症)的死亡率和风险增加相关。肥胖个体的体重减轻减少了许多这些风险因素,但体重减轻和维持可能非常困难。显然,开发治疗肥胖的新方法是一个重要目标,也是NIH肥胖研究战略计划的关键组成部分。治疗肥胖症的一种可能的新机制是α 7烟碱胆碱能受体的激活。尼古丁与体重减轻的关系,以及它抑制食欲、增加能量消耗和改变进食模式的能力已得到充分证实。最近的证据表明,α 7烟碱受体可能在这些效应中发挥特别突出的作用。我们小组分别研究非精神病受试者食物摄入行为的神经元机制和精神分裂症中烟碱胆碱能功能障碍的神经生物学的最新发现出人意料地收敛,表明肥胖个体中过度活跃的一些相同的大脑内在网络成分被患者中的α 7烟碱受体激动剂下调。鉴于这些作用,我们最近进行了α 7烟碱受体部分激动剂3- 2,4-二甲氧基苯亚甲基假木贼碱(DMXB-A)对患者的体重、食欲和对视觉食物线索的反应的神经元测量的作用的初步研究。这些措施是一项旨在检查药物对认知影响的研究的附加结果。与安慰剂相比,DMXB-A与显著的体重减轻以及饥饿和食欲减少有关。在神经元方面,DMXB-A与我们先前发现的与肥胖倾向个体相比,瘦人群对食物摄入的反应有关的相同大脑区域的改变有关。我们还发现,DMXB-A相关的对食物线索的反应变化与体重变化有关。考虑到这些初步结果,以及动物研究中出现的证据,α 7烟碱受体的激活可能是改变一般人群中超重/肥胖个体的食物摄入行为的神经元过程并改善体重管理的新机制。本申请的总体目标是了解α 7烟碱受体部分激动剂对一般人群中肥胖的神经、生理和行为机制的影响。希望这项研究的结果将告知
我们对烟碱胆碱能参与肥胖的认识,可能导致新的治疗策略,以解决对健康和生活质量产生负面影响的关键问题。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Targeting Functional Biomarkers in Schizophrenia with Neuroimaging.
- DOI:10.2174/1381612822666160127113912
- 发表时间:2016
- 期刊:
- 影响因子:3.1
- 作者:Wylie KP;Smucny J;Legget KT;Tregellas JR
- 通讯作者:Tregellas JR
Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.
- DOI:10.1093/ntr/nty034
- 发表时间:2018-08
- 期刊:
- 影响因子:0
- 作者:J. Tregellas;Korey P. Wylie
- 通讯作者:J. Tregellas;Korey P. Wylie
Effects of Dietary Protein and Fiber at Breakfast on Appetite, ad Libitum Energy Intake at Lunch, and Neural Responses to Visual Food Stimuli in Overweight Adults.
- DOI:10.3390/nu8010021
- 发表时间:2016-01-05
- 期刊:
- 影响因子:5.9
- 作者:Sayer RD;Amankwaah AF;Tamer GG Jr;Chen N;Wright AJ;Tregellas JR;Cornier MA;Kareken DA;Talavage TM;McCrory MA;Campbell WW
- 通讯作者:Campbell WW
Reproducibility assessment of brain responses to visual food stimuli in adults with overweight and obesity.
- DOI:10.1002/oby.21603
- 发表时间:2016-10
- 期刊:
- 影响因子:6.9
- 作者:Sayer, R. Drew;Tamer, Gregory G., Jr.;Chen, Ningning;Tregellas, Jason R.;Cornier, Marc-Andre;Kareken, David A.;Talavage, Thomas M.;McCrory, Megan A.;Campbell, Wayne W.
- 通讯作者:Campbell, Wayne W.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JASON R TREGELLAS其他文献
JASON R TREGELLAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JASON R TREGELLAS', 18)}}的其他基金
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10551293 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10209808 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Neuronal and behavioral effects of an implicit priming approach to improve eating behaviors in obesity
隐式启动方法改善肥胖饮食行为的神经元和行为效应
- 批准号:
10388376 - 财政年份:2021
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10038801 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10295165 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
减少海马过度活跃并改善精神分裂症患者的认知
- 批准号:
10671447 - 财政年份:2017
- 资助金额:
$ 35.42万 - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
8960808 - 财政年份:2015
- 资助金额:
$ 35.42万 - 项目类别:
Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults
烟碱激动剂对超重/肥胖成人的 BMI 和神经元反应的影响
- 批准号:
9307811 - 财政年份:2015
- 资助金额:
$ 35.42万 - 项目类别:
相似海外基金
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10412227 - 财政年份:2022
- 资助金额:
$ 35.42万 - 项目类别:
Discovery of a High Affinity, Selective and β-arrestin Biased 5-HT7R Agonist
发现高亲和力、选择性和β-抑制蛋白偏向的 5-HT7R 激动剂
- 批准号:
10610473 - 财政年份:2022
- 资助金额:
$ 35.42万 - 项目类别:
Supplement to Discovery of a high affinity, selective and beta-arrestinbiased 5-HT7R Agonist Grant
对高亲和力、选择性和 β 抑制偏向 5-HT7R 激动剂发现的补充补助金
- 批准号:
10799162 - 财政年份:2022
- 资助金额:
$ 35.42万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6639179 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6724797 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6636512 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6326889 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6266928 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
NMDA RECEPTOR--AGONIST AFFINITY, EFFICACY/TRANSDUCTION
NMDA 受体——激动剂亲和力、功效/转导
- 批准号:
6539099 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:
General Anesthetics and nAcCHOR Agonist Affinity
全身麻醉药和 nAcCHOR 激动剂亲和力
- 批准号:
6520329 - 财政年份:2001
- 资助金额:
$ 35.42万 - 项目类别:














{{item.name}}会员




